JRCT ID: jRCTs031180238
Registered date:12/03/2019
HLA-mismatched HSCT for standard-risk hematological disease using low-dose alemtuzumab
Basic Information
Recruitment status | Complete |
---|---|
Health condition(s) or Problem(s) studied | Patients with standard-risk advanced hematological disease |
Date of first enrollment | 21/10/2015 |
Target sample size | 23 |
Countries of recruitment | |
Study type | Interventional |
Intervention(s) | Conditioning regimen: Patients who are intolerable to conventional conditioning regimen due to either higher age (55>=), previous ASCT, organ dysfunction, or active infection will receive regimen 2-1 or 2-2.(Mainly, regimen 2-1 will be selected in patients with lymphoid malignancy and regimen 2-2 will be selected in patients with myeloid malignancy.) In patients who were not eligible for TBI-containing regimen, regimen 2-3 may be selected. The other patients will receive regimen 1. Regimen 1 Cyclophosphamide 60mg/kg/day iv. for 2 days TBI 2Gy twice daily for 3 days Alemtuzumab 0.25mg/kg/day iv. day-4,-3 (Maximum dose: 15mg/body/day for 2 days) *Cyclophosphamide may be replaced with fludarabine 30mg/m2/day iv. for 4 days Regime 2-1 Fludarabine 25mg/m2/day iv. for 5 days Melphalan 40mg/m2/day iv. for 2 days Alemtuzumab 0.25mg/kg/day iv. day-4,-3 (Maximum dose: 15mg/body/day for 2 days) Regimen 2-2 Fludarabine 30mg/m2/day iv. for 6 days Busulfan 3.2mg/kg/day iv. for 2-4 days TBI 2Gy once or twice daily for 1 day Alemtuzumab 0.25mg/kg/day iv. day-4,-3 (Maximum dose: 15mg/body/day for 2 days) Regimen 2-3 Fludarabine 30mg/m2/day iv. for 6 days Busulfan 3.2mg/kg/day iv. for 4 days Melphalan 80mg/m2/day iv. for 1 days Alemtuzumab 0.25mg/kg/day iv. day-4,-3 (Maximum dose: 15mg/body/day for 2 days) |
Outcome(s)
Primary Outcome | Disease-free survival at 1 year |
---|---|
Secondary Outcome | Overall survival, relapse rate, and non-relapse mortality at 1 year |
Key inclusion & exclusion criteria
Age minimum | >= 16age old |
---|---|
Age maximum | <= 70age old |
Gender | Both |
Include criteria | 1.Patients who do not have an available HLA-matched or one locus-mismatched related donor. 2.Patients who have a two- or three-locus-mismatched haploidentical related donor in good condition. 3.Patients who do not have an HLA-matched or one allele-mismatched unrelated donor, or patients whose disease status preclude time-consuming donor coordination. 4.Patients with standard-risk advanced hematological disease. High-risk acute leukemia, advanced CML, refractory malignant lymphoma, advanced MDS, acute or lymphoma type ATLL, advanced IPF or refractory severe aplastic anemia are regarded as advanced hematological disease, and in advanced disease, leukemia and malignant lymphoma in remission, MDS, IPF or severe aplastic anemia are included in stndard-risk group. 5.Patients who are 16 to 70 years old 6.Patients in performance status of 0 or 1. 7.Patients whose major organ functions are preserved. |
Exclude criteria | 1.Patients with poorly controlled active infection. 2.Patients with coexistence of malignancy. 3.Patients who are pregnant or nursing. 4.Patients with serious mental disorder. 5.Patients with HIV antibody positive. 6.Patients who are allergic to drugs used in conditioning regimen or GVHD prophylaxis. |
Related Information
Primary Sponsor | Kanda Yoshinobu |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) | UMIN000018283 |
Contact
Public contact | |
Name | Shinichi Kako |
Address | 1-847, Amanuma-cho, Omiya-ku, Saitama-shi, Saitama, Japan Saitama Japan 330-8503 |
Telephone | +81-48-647-2111 |
shinichikako@asahi-net.email.ne.jp | |
Affiliation | Jichi Medical University, Saitama Medical Center |
Scientific contact | |
Name | Yoshinobu Kanda |
Address | 1-847, Amanuma-cho, Omiya-ku, Saitama-shi, Saitama, Japan Saitama Japan 330-8503 |
Telephone | +81-48-647-2111 |
ycanda-tky@umin.ac.jp | |
Affiliation | Jichi Medical University, Saitama Medical Center |